You are here
Articles on Gastrointestinal Cancer
A selection of peer-reviewed articles on Gastrointestinal Cancer. All content available on the Advances in Gastrointestinal Cancer Resource Center, including original and review articles, interviews, guidelines and congress highlights, is independently selected by the members of the Editorial Board.
Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1)
Sook Ryun Park, Young Soo Park, Min-Hee Ryu, Baek-Yeol Ryoo, Chang Gok Woo, Hwoon-Yong Jung, Jeong Hoon Lee, Gin Hyug Lee, Yoon-Koo Kang
European Journal of Cancer, January 2016, Pages 42 - 50
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, et al.J Clin Oncol. 2016 Feb 16. [Epub ahead of print]
Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone
Robb WB, Messager M, Dahan L, Mornex F, Maillard E, D'Journo XB, et al.Br J Surg. 2016 Jan;103(1):117-25.
Impact of number of [(18) F]fluorodeoxyglucose-PET-positive lymph nodes on survival of patients receiving neoadjuvant chemotherapy and surgery for oesophageal cancer
Miyata H, Yamasaki M, Makino T, Tatsumi M, Miyazaki Y, Takahashi T, et al.Br J Surg. 2016 Jan;103(1):97-104.
A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer
Sudo K, Wang X, Xiao L, Wadhwa R, Shiozaki H, Elimova E, et al.J Natl Compr Canc Netw. 2016 Feb;14(2):173-9.
Restaging oesophageal cancer after neoadjuvant therapy with 18F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery
Findlay JM, Gillies RS, Franklin JM, Teoh EJ, Jones GE, di Carlo S, et al.Eur Radiol. 2016 Feb 16. [Epub ahead of print]
Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial
Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S, et al.BMC Cancer. 2016 Feb 8;16(1):68.
Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer
Shoda K, Ichikawa D, Fujita Y, Masuda K, Hiramoto H, Hamada J, et al.Gastric Cancer. 2016 Feb 13. [Epub ahead of print]